International: +1-347-960-6455
Benign Prostatic Hyperplasia (BPH) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

According to a new research report Benign Prostatic Hyperplasia (BPH) Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, the BPH therapeutics currently exhibits a proliferating pipeline with 15+ therapeutic candidates.

BPH Therapeutics Pipeline Insights

BPH can be identified as enlargement of prostate gland, a condition affects majority of male population. It is non-cancerous and goes through two main growth periods as a man age. The first phase begins in puberty, when the size of prostate becomes double. The second phase of prostate growth normally begins in the second decade of life. It is observed that men with a family history of BPH and chronic diseases such as heart disease, obesity, and diabetes are at higher risk of developing BPH. The condition thickens bladder wall, and eventually the bladder may weaken and lose the ability to empty completely. BPH is also associated with complications of urinary tract infection, bladder stones, kidney damage, and constant urge to urinate. The root cause of the disease remains unknown; however, increased level of estrogen is a suspected reason for the occurrence of this disease.

BPH can be diagnosed through physical examinations and medical tests, including digital rectal exam, urine test, blood test, prostate-specific antigen (PSA) test, and others. In severe cases, transrectal ultrasound, prostate biopsy, and cystoscopy are also performed. Uroxatral (Sanofi), Cardura (Pfizer Inc.), Flomax (Astellas Pharma Inc.), Proscar (Merck & Co. Inc.), Avodart (GlaxoSmithKline plc), Jalyn (GlaxoSmithKline plc), Cialis (Eli Lilly and Company), Hytrin (Abbott Laboratories), and Rapaflo (Allergan plc) are approved drugs available for the treatment of BPH.

Insights into Pipeline Segments

It has been observed during the research that majority of the drugs are designed as either alpha blockers or 5-alpha reductase inhibitors. Alpha-blockers primarily relax the bladder and prostate muscles; while, 5-alpha reductase inhibitors prevent further growth of prostate and help in shrinking it to relieve symptoms.

Positive Clinical Trial Results are Expected to Drive BPH Therapeutics Pipeline

Companies that are involved in developing therapeutics for BPH have shown positive clinical results in various phases of drug development. For instance, in January 2018, Nymox Pharmaceutical Corporation reported positive outcomes from the Phase III clinical study of fexapotide triflutate. According to the results, fexapotide demonstrated significant long-term benefit for BPH.

Browse Detailed Report at:

Global Market for BPH Therapeutics is Expected to Increase Statistically in the next 10 years

As of 2018, there were eight marketed products for BPH such as Uroxatral, Cardura, Flomax, Proscar, Avodart, Cialis, Hytrin, and Rapaflo. Sales of these drugs and emergence of products in pipeline are expected to boost the growth of the market in coming years.

Strategic Advancements Play a Pivotal Role in BPH Therapeutics Development

It has been observed that many pharmaceutical companies are entering into acquisitions for the development of BPH therapeutics and their geographical expansion. For instance, Boston Scientific Corporation announced the acquisition of NxThera Incorporated. Through this acquisition, Boston Scientific Corporation is likely to increase its BPH therapeutics portfolio.

Moreover, Sanofi, Abbott Laboratories, Pfizer Inc., Astellas Pharma Inc., Eli Lilly and Company, Merck & Co. Inc., Nymox Pharmaceutical Corporation, GlaxoSmithKline plc, Allergan plc, Veru Inc., Urovant Sciences Inc., and Caremark Limited are some of the key players involved in the development of therapeutic agents for BPH.

BPH Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of BPH. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the BPH therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to BPH.